Your browser doesn't support javascript.
loading
Interleukin-13 receptor α2 is a novel marker and potential therapeutic target for human melanoma.
Okamoto, Hayato; Yoshimatsu, Yasuhiro; Tomizawa, Taishi; Kunita, Akiko; Takayama, Rina; Morikawa, Teppei; Komura, Daisuke; Takahashi, Kazuki; Oshima, Tsukasa; Sato, Moegi; Komai, Mao; Podyma-Inoue, Katarzyna A; Uchida, Hiroaki; Hamada, Hirofumi; Fujiu, Katsuhito; Ishikawa, Shumpei; Fukayama, Masashi; Fukuhara, Takeshi; Watabe, Tetsuro.
Afiliación
  • Okamoto H; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
  • Yoshimatsu Y; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
  • Tomizawa T; Department of Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Kunita A; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
  • Takayama R; Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Morikawa T; Department of Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Komura D; Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Takahashi K; Department of Genomic Pathology, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Oshima T; Department of Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Sato M; Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Komai M; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
  • Podyma-Inoue KA; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
  • Uchida H; Department of Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Hamada H; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
  • Fujiu K; Project Division of Cancer Biomolecular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Ishikawa S; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
  • Fukayama M; Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Fukuhara T; Department of Advanced Cardiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Watabe T; Department of Genomic Pathology, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Sci Rep ; 9(1): 1281, 2019 02 04.
Article en En | MEDLINE | ID: mdl-30718742
Malignant melanoma is one of the untreatable cancers in which conventional therapeutic strategies, including chemotherapy, are hardly effective. Therefore, identification of novel therapeutic targets involved in melanoma progression is urgently needed for developing effective therapeutic methods. Overexpression of interleukin-13 receptor α2 (IL13Rα2) is observed in several cancer types including glioma and pancreatic cancer. Although IL13Rα2 is implicated in the progression of various types of cancer, its expression and roles in the malignant melanoma have not yet been elucidated. In the present study, we showed that IL13Rα2 was expressed in approximately 7.5% melanoma patients. While IL13Rα2 expression in human melanoma cells decreased their proliferation in vitro, it promoted in vivo tumour growth and angiogenesis in melanoma xenograft mouse model. We also found that the expression of amphiregulin, a member of the epidermal growth factor (EGF) family, was correlated with IL13Rα2 expression in cultured melanoma cells, xenograft tumour tissues and melanoma clinical samples. Furthermore, expression of amphiregulin promoted tumour growth, implicating causal relationship between the expression of IL13Rα2 and amphiregulin. These results suggest that IL13Rα2 enhances tumorigenicity by inducing angiogenesis in malignant melanoma, and serves as a potential therapeutic target of malignant melanoma.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Regulación Neoplásica de la Expresión Génica / Proliferación Celular / Subunidad alfa2 del Receptor de Interleucina-13 / Melanoma / Proteínas de Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Sci Rep Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Regulación Neoplásica de la Expresión Génica / Proliferación Celular / Subunidad alfa2 del Receptor de Interleucina-13 / Melanoma / Proteínas de Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Sci Rep Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido